Erythropoietin — Red Blood Cell Hormone

Erythropoietin (often abbreviated as EPO) is an endocrine hormone synthesised primarily by peritubular interstitial cells in the adult kidneys, with small amounts produced by the liver. Its release is triggered by renal cellular hypoxia—a state where oxygen delivery falls below physiological requirements. EPO travels via the bloodstream to bind specific receptors on erythroid progenitor cells in the bone marrow.

Once bound, erythropoietin initiates intracellular signalling cascades that promote the survival, proliferation, and terminal differentiation of erythroblasts into mature erythrocytes. Synthetic formulations, known as erythropoiesis-stimulating agents (ESAs), replicate natural EPO to treat severe chronic anaemia in selected oncology settings.

Anaemia is common in cancer and causes fatigue, breathlessness, dizziness, and diminished quality of life. Tracking erythropoietin dynamics helps doctors differentiate between anaemia of chronic disease, renal dysfunction, and nutritional deficits. In specific situations, synthetic erythropoietin agents can reduce the requirement for donor blood transfusions during myelosuppressive chemotherapy. However, because ESAs carry potential risks, including blood clots and possible impacts on tumour growth, treatment decisions require careful clinical consideration between oncologists and patients.

Serum erythropoietin levels can be quantified using a specialised venous blood test alongside a full blood count, reticulocyte count, ferritin, and transferrin saturation. Measuring EPO helps determine whether the kidneys are responding normally to anaemia. EPO is not a primary diagnostic cancer biomarker, but rather a functional laboratory indicator of haematopoietic and renal regulation.

Erythropoietin is relevant across cancers treated with intensive chemotherapy, including breast, lung, ovarian, and colorectal cancers, as well as lymphomas. It is also clinically significant in renal cell carcinoma, which can occasionally secrete excess erythropoietin and cause abnormally high red blood cell counts (paraneoplastic polycythemia), as well as in multiple myeloma and myelodysplastic syndromes.

When indicated, synthetic forms such as epoetin alfa or darbepoetin alfa are administered via subcutaneous injection to stimulate red blood cell production. Clinical guidelines from international societies recommend using these agents cautiously, specifically in patients receiving concurrent palliative chemotherapy when haemoglobin falls below specified thresholds. Careful dosing aims to maintain the lowest haemoglobin level necessary to avoid blood transfusion, minimising thromboembolic risks.